-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Pardes Biosciences (NASDAQ:PRDS) Coverage Initiated by Analysts at JMP Securities
Pardes Biosciences (NASDAQ:PRDS) Coverage Initiated by Analysts at JMP Securities
JMP Securities initiated coverage on shares of Pardes Biosciences (NASDAQ:PRDS – Get Rating) in a research report sent to investors on Tuesday, The Fly reports. The firm issued a market outperform rating and a $9.00 price objective on the stock.
Separately, SVB Leerink cut their price target on shares of Pardes Biosciences from $18.00 to $12.00 and set an outperform rating for the company in a research note on Tuesday, August 16th.
Get Pardes Biosciences alerts:Pardes Biosciences Trading Up 3.5 %
NASDAQ PRDS opened at $1.19 on Tuesday. The firm has a 50-day simple moving average of $1.23 and a 200 day simple moving average of $2.62. Pardes Biosciences has a twelve month low of $0.75 and a twelve month high of $17.76.
Pardes Biosciences (NASDAQ:PRDS – Get Rating) last announced its quarterly earnings results on Monday, November 7th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.09. As a group, sell-side analysts expect that Pardes Biosciences will post -1.77 earnings per share for the current fiscal year.Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRDS. RA Capital Management L.P. increased its holdings in shares of Pardes Biosciences by 97.5% during the first quarter. RA Capital Management L.P. now owns 6,175,038 shares of the company's stock worth $44,584,000 after buying an additional 3,048,000 shares in the last quarter. VK Services LLC acquired a new stake in shares of Pardes Biosciences during the second quarter worth approximately $18,886,000. Goldman Sachs Group Inc. increased its holdings in shares of Pardes Biosciences by 102.4% during the second quarter. Goldman Sachs Group Inc. now owns 4,275,914 shares of the company's stock worth $13,127,000 after buying an additional 2,163,503 shares in the last quarter. Lynx1 Capital Management LP increased its holdings in shares of Pardes Biosciences by 4.4% during the third quarter. Lynx1 Capital Management LP now owns 2,275,732 shares of the company's stock worth $4,210,000 after buying an additional 95,172 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new stake in shares of Pardes Biosciences during the first quarter worth approximately $15,025,000. Institutional investors own 75.06% of the company's stock.
Pardes Biosciences Company Profile
(Get Rating)
Pardes Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases.
Featured Stories
- Get a free copy of the StockNews.com research report on Pardes Biosciences (PRDS)
- We Are the Champions: 3 Dividend Growers Wall Street Loves
- Will Nordstrom Stock be the Grinch This Year?
- Harpoon Therapeutics Remains Volatile After Promising News
- What is Market Structure in Trading?
- Institutional Selling Is No Headwind For Nike
Receive News & Ratings for Pardes Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pardes Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
JMP Securities initiated coverage on shares of Pardes Biosciences (NASDAQ:PRDS – Get Rating) in a research report sent to investors on Tuesday, The Fly reports. The firm issued a market outperform rating and a $9.00 price objective on the stock.
据The Fly报道，JMP证券在周二发给投资者的一份研究报告中启动了对Pardes Biosciences(纳斯达克：PRDS-GET评级)股票的报道。该公司对该股发布了表现优于市场的评级和9.00美元的目标价。
Separately, SVB Leerink cut their price target on shares of Pardes Biosciences from $18.00 to $12.00 and set an outperform rating for the company in a research note on Tuesday, August 16th.
另外，SVB Leerink在8月16日周二的一份研究报告中将Pardes Biosciences的目标价从18.00美元下调至12.00美元，并为该公司设定了表现优于大盘的评级。
Pardes Biosciences Trading Up 3.5 %
Pardes Biosciences股价上涨3.5%
NASDAQ PRDS opened at $1.19 on Tuesday. The firm has a 50-day simple moving average of $1.23 and a 200 day simple moving average of $2.62. Pardes Biosciences has a twelve month low of $0.75 and a twelve month high of $17.76.
纳斯达克PRDS周二开盘报1.19美元。该公司的50日简单移动均线切入位在1.23美元，200日简单移动均线切入位在2.62美元。Pardes Biosciences的12个月低点为0.75美元，12个月高位为17.76美元。
Institutional Inflows and Outflows
机构资金流入和流出
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRDS. RA Capital Management L.P. increased its holdings in shares of Pardes Biosciences by 97.5% during the first quarter. RA Capital Management L.P. now owns 6,175,038 shares of the company's stock worth $44,584,000 after buying an additional 3,048,000 shares in the last quarter. VK Services LLC acquired a new stake in shares of Pardes Biosciences during the second quarter worth approximately $18,886,000. Goldman Sachs Group Inc. increased its holdings in shares of Pardes Biosciences by 102.4% during the second quarter. Goldman Sachs Group Inc. now owns 4,275,914 shares of the company's stock worth $13,127,000 after buying an additional 2,163,503 shares in the last quarter. Lynx1 Capital Management LP increased its holdings in shares of Pardes Biosciences by 4.4% during the third quarter. Lynx1 Capital Management LP now owns 2,275,732 shares of the company's stock worth $4,210,000 after buying an additional 95,172 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new stake in shares of Pardes Biosciences during the first quarter worth approximately $15,025,000. Institutional investors own 75.06% of the company's stock.
一些对冲基金和其他机构投资者最近增持或减持了PRDS的股份。Ra Capital Management L.P.在第一季度增持了Pardes Biosciences的股票97.5%。Ra Capital Management L.P.现在持有该公司6,175,038股股票，价值44,584,000美元，上个季度又购买了3,048,000股。VK Services LLC在第二季度收购了Pardes Biosciences的新股份，价值约18,886,000美元。高盛股份有限公司在第二季度增持了帕德斯生物科学公司的股票102.4%。高盛股份有限公司现在持有该公司4,275,914股股票，价值13,127,000美元，该公司在上个季度又购买了2,163,503股。Lynx1 Capital Management LP在第三季度增持了Pardes Biosciences的股票4.4%。Lynx1 Capital Management LP在上个季度额外购买了95,172股后，现在拥有2,275,732股该公司股票，价值4,210,000美元。最后，弗雷泽生命科学管理公司在第一季度收购了帕德斯生物科学公司价值约15,025,000美元的新股份。机构投资者持有该公司75.06%的股份。
Pardes Biosciences Company Profile
Pardes Biosciences公司简介
(Get Rating)
(获取评级)
Pardes Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases.
Pardes Biosciences，Inc.是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，以改善威胁生命的疾病患者的生活。它的主要候选药物是处于临床开发阶段的PBI-0451，用于治疗和预防严重急性呼吸综合征冠状病毒2型感染和相关疾病。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Pardes Biosciences (PRDS)
- We Are the Champions: 3 Dividend Growers Wall Street Loves
- Will Nordstrom Stock be the Grinch This Year?
- Harpoon Therapeutics Remains Volatile After Promising News
- What is Market Structure in Trading?
- Institutional Selling Is No Headwind For Nike
- 免费获取StockNews.com关于Pardes Biosciences的研究报告(PRDS)
- 我们是冠军：华尔街钟爱的3位股息种植者
- 诺德斯特龙股票公司会成为今年的格林奇吗？
- 鱼叉治疗公司在有希望的消息传出后仍不稳定
- 交易中的市场结构是什么？
- 机构销售对耐克来说不是逆风
Receive News & Ratings for Pardes Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pardes Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受帕德斯生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Pardes Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧